In addition, anti-cancer therapy which combine PARP inhibition and genotoxic chemotherapeutic agents according to the expression of PARP1, γH2AX, BRCA1, and BRCA2 has been suggested for breast carcinomas [37] and Ewing sarcomas [38, 40]. This evidence concerns the gene PARP1 and breast carcinoma.